Overview

Evaluate the Effects of Famotidine or Rabeprazole on the PK of Nirogacestat

Status:
RECRUITING
Trial end date:
2025-11-01
Target enrollment:
Participant gender:
Summary
This study will evaluate the effects of the H2 blocker famotidine or the PPI rabeprazole on the PK of nirogacestat in healthy male participants
Phase:
PHASE1
Details
Lead Sponsor:
SpringWorks Therapeutics, Inc.
Treatments:
Amyloid Precursor Protein Secretases
Famotidine
Histamine H2 Antagonists
nirogacestat
Proton Pump Inhibitors
Rabeprazole